AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Antibodies for Diagnosis and Treatment of Breast Cancer (Yissum)

Antibodies generated against mouse lymphoma cells that harbor the virus MMTV (mouse mammary tumor virus) were used to recognize human breast cancer.

These antibodies can be used either in their current forms or in modified forms for diagnosis, prognosis, and subsequent treatment of certain human breast cancers.

Working on proving correlation of appearance of p14 antibodies with human breast cancers

Positive multi-sample trials will enable proof of p14 antibodies as diagnosticAntibodies generated against mouse lymphoma cells that harbor MMTV recognize p14, the leader sequence (N-terminal peptide) of the precursor of the envelope protein of MMTV, and are used for immunohistochemical analysis of human breast cancers. Monoclonal antibodies to p14 can be subsequently humanized to treat breast cancer patients that express p14. Alternatively, P14 may be used as a vaccination against breast cancer.Completely new approach to diagnosis and treatment of certain human breast cancers

Possibility of development of vaccine against breast cancers containing MMTVLarge multi-sample trials needed to prove diagnostic capability

Study of possibility of correlating presence of p14 or p14 antibodies in women’s sera with prognosi
Technology Benefits
According to a SEER estimate, more than 200,000 new cases of breast cancer are diagnosed annually in the United States alone.

Recent reports claim that about 38% of human breast cancers may contain sequences related to MMTV.

Positive results obtained in mice and in small number of human samples.

Breast cancer has the highest incidence (32%) and is the second most cause for cancer death (15%) in U.S. women. Breast cancer treatment costs about $7 billion each year.
ID No.

For more information, please click Here
Mobile Device